<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076698</url>
  </required_header>
  <id_info>
    <org_study_id>1317 FRANCE</org_study_id>
    <nct_id>NCT02076698</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy</brief_title>
  <acronym>FRANCE</acronym>
  <official_title>Clinical and Medico-economical Assessment of Deep Brain Stimulation of the Anterior Nucleus of the Thalamus for the Treatment of Pharmacoresistant Partial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is twofold:

        1. Assess the clinical efficacy of DBS on epilepsy according to their number and severity
           at 1 year follow up.

        2. Perform a cost-effectiveness analysis from the perspective of Medicare at 1 and 2 years.

      The study hypothesis is that thalamic DBS (neurostimulation of the anterior nucleus of the
      thalamus) will decrease significantly, the frequency (potentially 50% reduction in severe
      crises) of the most severe seizures, in at least 50% of patients who have drug-resistant
      partial epilepsy; and should also improve significantly the quality of life through a gain of
      independence in activities of daily life, the possible recovery of functional abilities,
      recovery of social or professional activities.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of effectiveness of thalamic DBS on seizures severity</measure>
    <time_frame>2 years</time_frame>
    <description>The main objective of the study is twofold : to assess the effectiveness of DBS on seizures according to their severity at 1 year follow up and to perform a cost-effectiveness analysis from the perspective of Medicare at 1 and 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-utility analysis from the perspective of Medicare</measure>
    <time_frame>2 years</time_frame>
    <description>Perform a cost-utility analysis from the perspective of Medicare at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the improvement of quality of life and overall neuropsychological impact</measure>
    <time_frame>2 years</time_frame>
    <description>Compare the improvement of quality of life and overall neuropsychological impact at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison the adverse effects (including depression)</measure>
    <time_frame>2 years</time_frame>
    <description>Compare the adverse events (special focus on depression) at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of th new therapeutic strategy on the hospital budget</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the impact on the hospital budget for the introduction of this therapeutic strategy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Partial Epilepsy</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>AN-DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep Brain Stimulation of the Anterior Nucleus of the thalamus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual treatment of epilepsy including vagus nerve stimulation (VNS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AN-DBS</intervention_name>
    <description>Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment</description>
    <arm_group_label>AN-DBS</arm_group_label>
    <other_name>Deep Brain Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual treatment</intervention_name>
    <description>usual treatment of epilepsy Vagus nerve stimulation: maintained</description>
    <arm_group_label>Usual treatment</arm_group_label>
    <other_name>Treatment of epilepsy including vagus nerve stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with focal or multifocal epilepsy with or without secondary generalized
             seizure inoperable at the time of inclusion

          -  Failure of pharmacological therapies (pharmacoresistant epilepsy) for over 4 years
             (persistent seizures despite at least two anti-epileptic treatments used at the
             optimal dose for at least 2 years)

          -  Failure of vagus nerve stimulation, defined as the persistence of crises considered
             debilitating after 2 years of VNS's treatment

          -  VNS failure in a patient treated with VNS, for less than 2 years. with stop early due
             to the worsening crisis

          -  Intelligence quotient above 55

          -  Have the written consent of the legal representative for patients under guardianship
             and minors

          -  Affiliation to the french social security system or equivalent

          -  People who signed the consent form

          -  Seizure frequency at least 4 crisis / month on average for at least 3 months, about 12
             crisis in 3 months objectified by the neurologist during visit pre-inclusion, and
             confirmed by the neurologist after 3 months of Baseline during the inclusion visit

        Exclusion Criteria:

          -  Patient with a generalized epilepsy Immediately

          -  Patient with a simple partial seizures (subjective manifestations only)

          -  Patient with a cons-indication for MRI, a serious intercurrent disease, a progressive
             brain tumor

          -  Patient with a suicide risk of in the six months preceding the inclusion visit (score
             ≥ 2 on item 10 of the Montgomery-Asberg Depression Rating Scale)

          -  Patient a surgical or anesthetic cons-indication

          -  Patient with anticoagulant or antiplatelet treatment in the long term

          -  Woman of childbearing potential without effective contraception, or pregnant or
             lactating

          -  People hospitalized without consent

          -  People deprived of freedom

          -  Patient currently participating in another clinical research, or who participated in a
             clinical study in the month preceding the pre-inclusion visit (except for any
             non-interventional research)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan CHABARDES, MDPHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra DAVID-TCHOUDA, MD</last_name>
    <phone>0033476767186</phone>
    <email>SDavidTchouda@chu‐grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine MASSICOT, CRA</last_name>
    <phone>0033476768860</phone>
    <email>SMassicot@chu‐grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume PENCHET, MD</last_name>
      <phone>0033556795518</phone>
      <email>guillaume.penchet@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume PENCHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel CUNY, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan CHABARDES, MD, PHD</last_name>
      <phone>0033476769385</phone>
      <email>SChabardes@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphan CHABARDES, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe KAHANE, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe DERAMBURE, MD, PHD</last_name>
      <phone>0033320446461</phone>
      <email>philippe.derambure@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe DERAMBURE, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc GUENOT, MD,PHD</last_name>
      <phone>0033472118900</phone>
      <email>marc.guenot@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marc GUENOT, MDPHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe RYVLIN, MDPHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie REGIS, MDPHD</last_name>
      <phone>0033491386564</phone>
      <email>JeanMarie.REGIS@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marie REGIS, MDPHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice BARTOLOMEI, MDPHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe COUBES, MDPHD</last_name>
      <phone>0033467337262</phone>
      <email>p-coubes@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe COUBES, MDPHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blanca MERCEDES ALVAREZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie COLNAT-COULBOIS, MD</last_name>
      <phone>0033383851579</phone>
      <email>s.coulbois@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie COLNAT-COULBOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis MAILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denys FONTAINE, MD</last_name>
      <phone>0033492038450</phone>
      <email>fontaine.d@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Denys FONTAINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre THOMAS, MDPHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg DORFMULLER, MD</last_name>
      <phone>0033148036817</phone>
      <email>gdorfmuller@fo-rothschild.fr</email>
    </contact>
    <investigator>
      <last_name>Georg DORFMULLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde CHIPAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sainte Anne Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand DEVAUX, MDPHD</last_name>
      <phone>0033145658258</phone>
      <email>B.DEVAUX@ch-sainte-anne.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand DEVAUX, mdphd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francine CHASSOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of La Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CLEMENCEAU, MD</last_name>
      <phone>0033142163408</phone>
      <email>stephane.clemenceau@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane CLEMENCEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca NICA, MD</last_name>
      <phone>0033299284257</phone>
      <email>anca.pasnicu@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Anca NICA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud BIRABEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire HAEGELEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard HIRSCH, MDPHD</last_name>
      <phone>0033388116768</phone>
      <email>Edouard.Hirsch@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Edouard HIRSCH, MDPHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jimmy VOIRIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe SOL, MDPHD</last_name>
      <phone>0033561322932</phone>
      <email>sol.jc@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe SOL, MDPHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc VALTON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Chabardès S, Kahane P, Minotti L, Koudsie A, Hirsch E, Benabid AL. Deep brain stimulation in epilepsy with particular reference to the subthalamic nucleus. Epileptic Disord. 2002 Dec;4 Suppl 3:S83-93.</citation>
    <PMID>12495878</PMID>
  </reference>
  <reference>
    <citation>Chabardès S, Minotti L, Chassagnon S, Piallat B, Torres N, Seigneuret E, Vercueil L, Carron R, Hirsch E, Kahane P, Benabid AL. [Basal ganglia deep-brain stimulation for treatment of drug-resistant epilepsy: review and current data]. Neurochirurgie. 2008 May;54(3):436-40. doi: 10.1016/j.neuchi.2008.02.039. Epub 2008 May 2. Review. French.</citation>
    <PMID>18452956</PMID>
  </reference>
  <reference>
    <citation>Fisher R, Salanova V, Witt T, Worth R, Henry T, Gross R, Oommen K, Osorio I, Nazzaro J, Labar D, Kaplitt M, Sperling M, Sandok E, Neal J, Handforth A, Stern J, DeSalles A, Chung S, Shetter A, Bergen D, Bakay R, Henderson J, French J, Baltuch G, Rosenfeld W, Youkilis A, Marks W, Garcia P, Barbaro N, Fountain N, Bazil C, Goodman R, McKhann G, Babu Krishnamurthy K, Papavassiliou S, Epstein C, Pollard J, Tonder L, Grebin J, Coffey R, Graves N; SANTE Study Group. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010 May;51(5):899-908. doi: 10.1111/j.1528-1167.2010.02536.x. Epub 2010 Mar 17.</citation>
    <PMID>20331461</PMID>
  </reference>
  <reference>
    <citation>Lim SN, Lee ST, Tsai YT, Chen IA, Tu PH, Chen JL, Chang HW, Su YC, Wu T. Electrical stimulation of the anterior nucleus of the thalamus for intractable epilepsy: a long-term follow-up study. Epilepsia. 2007 Feb;48(2):342-7.</citation>
    <PMID>17295629</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>Anterior Nucleus of thalamus</keyword>
  <keyword>Treatment refractory</keyword>
  <keyword>Pharmacoresistant partial epilepsy</keyword>
  <keyword>vagus nerve stimulation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

